Publications

Activity of Aztreonam-Avibactam and Comparators against Difficult-to- Treat Resistant (DTR) Enterobacterales from Patients with Pneumonia or Intra-abdominal Infections (IAI) in European Medical Centers (2020-2024). Lead author: Helio S. Sader, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #1273

Activity of manogepix against Candida auris. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3308

Activity of manogepix against invasive fungal infections from immunocompromised hosts. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3309

Activity of Manogepix and Comparator Antifungals Against Mould Isolates Collected from Invasive Infections in Intensive Care Units (ICU) and Non-ICU Settings (2017–2024). Lead author: Michael Huband, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3320

Activity of Manogepix and Comparator Antifungal Agents Against Yeast Isolates Collected from Invasive Infections in Intensive Care Unit (ICU) and Non-ICU Settings. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3310

Isavuconazole activity against moulds in ICU and non-ICU infections. Lead author: SJ Ryan Arends, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3303

Comparison of manogepix activity against 2,659 community-acquired and nosocomial mould isolates from the SENTRY Antimicrobial Surveillance Program (2017–2024). Lead author: Michael Huband, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3309

Lefamulin Activity against Bacterial Pathogens Typically Causing Community-Acquired Pneumonia Collected from European Medical Centres in 2023 and 2024. Lead author: Helio S. Sader, presented at ESCMID Global 2026, April 20, Munich, Germany
P #1245

Activity of rezafungin against Aspergillus spp. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3304

Isavuconazole activity against moulds in nosocomial and community-acquired infections. Lead author: SJ Ryan Arends, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3312

Activity of tebipenem against Enterobacterales, including molecularly characterized isolates causing urinary tract and bloodstream infections in the United States and United Kingdom in 2023-2024. Lead author: Timothy Doyle, presented at ESCMID Global 2026, April 19, Munich, Germany
Poster #2644

In vitro Activity of Zosurabalpin and Comparator Agents Tested Against Acinetobacter baumannii-calcoaceticus Complex Isolates From China. Lead author: Joshua M. Maher, presented at APCCMI 2025, Nov 3, Bangkok, Thailand
Poster #RES-162

In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024.  Lead authors: R Kapoor, TB Doyle, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA

Poster #P1214

In Vitro Activity of Cefiderocol against Resistant Subsets of Pseudomonas aeruginosa Collected from United States Hospitals during 2020–2024. Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1287

Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized ESBL- and carbapenemase-positive subsets causing urinary tract infections in United States Medical Centers (2023). Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1203

In vitro activity of gepotidacin and comparator agents against a collection of Escherichia coli and Klebsiella pneumoniae urine isolates from the United States during 2023. Lead author: S.J. Ryan Arends, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1174

Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in United States Medical Centers (2023). Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1204

In vitro activity of EL219 (SF001) and amphotericin B agents against a collection of Candida and Aspergillus isolates collected in 2024. Lead author: S.J. Ryan Arends, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1205

Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023. Lead authors: R Kapoor, TB Doyle, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA

Poster #P1213

Activity of omadacycline against multidrug-resistant and molecularly characterized Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria

Poster #P1314

Gepotidacin activity against and analysis of susceptibility to oral standard-of-care antibiotics for urinary tract infections caused by Escherichia coli and Klebsiella pneumoniae collected in Europe in 2023. Lead author: S. J. Ryan Arends, presented at ESCMID Global 2025, April 14, Vienna, Austria

Poster #P1216

Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria

Poster #P1351

Gepotidacin activity against E. coli and K. pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria

Poster #P1216

Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria

Poster #P1349

Activity of manogepix against a worldwide collection of yeast isolates from 2023. Lead author: Marisa L. Winkler, presented at ESCMID Global 2025, April 12, Vienna, Austria

Poster #P2891

In vitro Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Responsible for Urinary Tract Infections in the US (2019–2022). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1060

Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from United States medical centers (2019–2023)Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1081

In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized ESBL and Carbapenemase Positive Subsets Causing Urinary Tract Infections in the United States (2019–2022).  Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1059

In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized Fluoroquinolone Not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019–2022).  Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1061

In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of Klebsiella pneumoniae Urine Isolates Collected from the United States during 2019–2022.  Lead author: S. J. Ryan Arends, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #1062

Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023).  Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1080

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of Stenotrophomonas maltophilia Isolates Collected in United States Medical Centers (2019–2023). Lead author: Timothy B. Doyle, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1083

Activity of rezafungin against clinical isolates of uncommon species of Candida spp.  Lead author: Marisa L. Winkler, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #1095

Activity of Ibrexafungerp and Comparator Antifungals Tested Against Candida and Aspergillus Isolates Collected from Invasive Infections in a Global Surveillance Program in 2023. Lead author: Marisa L. Winkler, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1096

Activity of Isavuconazole and Comparator Agents against Pediatric Fungal Isolates Collected from 2017–2023 in a Global Surveillance Program.  Lead author: Marisa L. Winkler, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1168

In vitro Activity of Ceftobiprole Against Prominent Methicillin-resistant Staphylococcus aureus Clonal Groups Collected Through the SENTRY Antimicrobial Surveillance Program. Lead author: John H. Kimbrough, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1526

Update on the Activity of Ceftobiprole against Gram-positive Clinical Bacterial Isolates Causing Skin and Skin-structure Infections in the United States (2016–2020). Lead author: Joshua M. Maher, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P1527

In vitro activity of omadacycline and comparator agents against a collection of Neisseria gonorrhoeae urine isolates collected from the United States during 2018-2020. Lead author: S.J. Ryan Arends, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #1528

Surveillance of omadacycline in vitro activity against 35,000 bacterial clinical isolates from the United States (2019–2023). Lead author: Michael D. Huband, IDWeek 2024, October 16-19, Los Angeles, CA, USA

Poster #P411

Activity of gepotidacin against Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2019–2022).  Lean Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain

Poster #P1441

In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of Klebsiella pneumoniae Urine Isolates Collected from Europe during 2019–2022.  Presenting Author: S. J. Ryan Arends, Ph.D., at ECCMID, 27-30 April 2024, Barcelona, Spain

Poster #2433

In Vitro Antimicrobial Activity of Taurolidine against Associated with Catheter-Related Bloodstream Infections. Lead authors: Jared L. Crandon, PharmD presented at SHEA Spring Conference 2024 Houston, TX
Poster #130

Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program.  Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2115

Delafloxacin and Comparator Fluoroquinolones In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022).  Lead author: Michael D. Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2754

In Vitro Antimicrobial Activity of Taurolidine against Candida auris Bloodstream Isolates from Global Sources.  Lead author: Antony Pfaffle, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2117

Activity of Ceftobiprole Against Enterococcus faecalis Clinical Isolates From the United States (2016–2020), Including Those From Difficult-to-Treat Infections.  Lead author: Rodrigo Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2173

In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020).  Lead author: Leonard Duncan, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2162

Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in the United States in 2022.  Lead author: S.J. Ryan Arends, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2159

Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints.  Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #P2113

Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022).  Lead author: Michael D. Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #1292